Focus Areas

COPD affects 5 % of the global population and is the third-leading cause of death worldwide; 3 million patients each year. The current treatment addresses the symptoms only, so there is a huge medical need for truly effective anti-inflammatory drugs to treat this rapidly growing group of patients.

Therefore Sulfateq sees great potential for the anti-inflammatory component of our compounds in the drug development activities related to COPD.